Novo Nordisk is touting the first Phase III success for its once-weekly GLP-1 therapy semaglutide. The Danish pharma company says that two doses of the drug–a key part of the pipeline–slashed HbA1c levels by 1.5% and 1.6%.

…read more

Source: Novo heralds promising PhIII diabetes data for once-weekly semaglutide


0 No comments